Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS Cash & Equivalents

Cash & Equivalents at other companies

Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Amgen logo
AmgenAMGN
$559M+10.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$390.73M+551%

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.49B+63.7%
Enterprise value$3.03B+115%
P/S154.5×+109×

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's cash & equivalents?
NewAmsterdam Pharma Company (NAMS) reported cash & equivalents of $457.61M in Q1 2026.
How has NewAmsterdam Pharma Company's cash & equivalents changed year-over-year?
NewAmsterdam Pharma Company's cash & equivalents decreased by 38.9% year-over-year, from $748.42M to $457.61M.
What is the long-term trend for NewAmsterdam Pharma Company's cash & equivalents?
Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's cash & equivalents has grown at a 1.6% compound annual growth rate (CAGR), from $467.73M to $490M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.